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ABSTRACT 
Depression is a disease that has an estimated lifetime prevalence of ~15% and a 
heritability of ~36%. There is support for a heterogeneous etiology of depression, 
which includes a) numerous genetic loci, b) various epigenetic contributors, and c) 
different environmental risk factors. The first five papers included in the present thesis 
investigate these three disease-contributing categories by studying a) the association of 
P11, NPY, MAOA and NR3C1, with depression, b) epigenetic marks like DNA 
methylation and histone modifications, and c) environmental influences, like childhood 
adversities, that may interact with certain genotypes and modulate the risk of 
depression. In two of these studies, there is also an attempt to pinpoint some targets and 
mechanisms of a current antidepressant drug and to examine the molecular effects of 
novel potential therapeutics. The thesis also includes a paper which investigates reasons 
behind public refusal to consent to participation in a human genetics repository; a so-
called DNA biobank. Achieving high participation rates in DNA biobanks is a 
prerequisite for the identification of new genetic loci, already known to have small 
effect sizes, which are associated with complex disorders like depression. However, as 
addressed in this last paper, solidarity (i.e. the participation in research for the common 
good) seems to be at stake for DNA biobanks and is an issue that needs to be raised 
both by the scientific community and national policy-makers. Specifically, the data of 
this thesis 1) confirm a genetic association between NPY and depression, 2) show the 
existence of a MAOA x childhood-adversity interaction that increases the risk of 
depression, 3) demonstrate DNA methylation differences of P11 in depression-like 
states and of MAOA in depression, 4) verify the effect of childhood trauma on NR3C1 
DNA methylation, 5) provide new insights into how Npy is transcriptionally regulated 
via an allele-specific epigenetic programming and describe an alternatively spliced Npy 
mRNA variant, 6) suggest that escitalopram (a selective serotonin reuptake inhibitor; 
SSRI) may exert part of its antidepressant function by affecting the expression of DNA 
methyltransferases (DNMTs) and DNA methylation levels, 7) support the 
antidepressant effect of running, and 8) provide awareness of the ethical problems 
posed by large-scale genomic studies that rely on DNA biobanking.  
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1. INTRODUCTION 
The concept of depression was coined by the ancient Greek physician Hippocrates (c. 
460 BC – c. 370 BC) who referred to this state using the term melancholy, as it was 
thought to be caused by an excess of black bile [melas (μέλας) = black and choly 
(χολή) = bile; (1)]. Today, depression is defined as a mental disorder that is 
characterized by low mood and self-esteem, and loss of interest or pleasure in 
commonly enjoyable activities (2, 3). Up to 75% of those with depression also suffer 
from anxiety (4, 5), and other types of comorbidity include those of substance abuse 
(6), post-traumatic stress disorder (7), cardiovascular disease and diabetes (8). 
Depression occurs more often in females than in males [female-to-male ratio of about 
2:1 (9)] and its lifetime prevalence is ~13% in Europe (10) and ~17% in North America 
(11). However, recent reports indicate that the latter estimates may actually be too low 
(12). The importance of studying depression is also indicated by the global projections 
of burden of disease provided by the World Health Organization [WHO; (13)]. More 
specifically, the three leading causes of burden of disease in 2030, ranked in 
descending order, are projected to include acquired immunodeficiency syndrome 
(HIV/AIDS), depression (unipolar depressive disorder), and ischemic heart disease 
(14).  
 
The introductory section of this dissertation will provide some main definitions and 
background information on the terms and topics that are referred to and studied in the 
constituent papers. Hopefully, this will assist each reader in understanding the 
presented data and their putative clinical significance, in addition to the thesis’ 
contribution to the field of psychiatric genetics and to the deciphering of the molecular 
etiology of depression. 
 
 
 
 
 
 
“If you are depressed you are living in the past.  
If you are anxious you are living in the future.  
If you are at peace you are living in the present.”  
– Lao Tzu 
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1.1. DEPRESSION – IN GENERAL 
This section will provide a general overview of how depression is diagnosed, what is 
known about the factors that contribute to its pathogenesis, the main brain structures 
that are affected, and the primary treatment options. 
 
 
1.1.1. Definition and diagnosis 
Depression is a disease that is classified under the mood (affective) disorders and is 
diagnosed by general practitioners, psychiatrists or psychologists based on the criteria 
of the American Psychiatric Association’s revised fourth edition of the Diagnostic and 
Statistical Manual of Mental Disorders [DSM-IV; (2)] or the World Health 
Organization’s 10th revision of the International Statistical Classification of Diseases 
and Related Health Problems [ICD-10; (3)]. Based on DSM-IV and ICD-10, a 
diagnosis of depression is given when main depressive symptoms (depressed mood, 
anhedonia, and reduced energy) persist for at least two weeks. While the use of these 
two instruments involves subjective self-reports and observations, there is also 
promising ongoing research focusing on the development of clinical tests that can 
detect biological markers (biomarkers) associated with this disease (15). Screening for 
biomarkers in e.g. blood will potentially provide an objective diagnosis method in the 
future. Finally, a distinction must be made between unipolar disorder (a.k.a. clinical or 
major or unipolar depression; which is the research topic of this thesis and will from 
now on only be referred to as depression) and bipolar disorder [a.k.a. manic-depressive 
disorder and usually defined by the presence of at least one manic or hypomanic 
episode, with or without depressive episodes; (2, 3)]. 
 
1.1.2. Etiology 
There is an etiological relationship between mood disorders, like depression, and a 
number of behavioral, biological and psychosocial factors (16). With regard to biology, 
depression belongs to the so-called complex genetic disorders, meaning that multiple 
genes, in combination with chance, lifestyle, epigenetic and environmental factors, play 
a role in the disorder’s pathogenesis (17-19). With regard to the genetic component, a 
Swedish national twin study estimated that the heritability of liability to depression is 
~36%, which averages two highly different figures of 42% for women and 29% for 
men (20). With regard to the environmental influences, stressful life events (e.g. death, 
assault, marital problems, job loss, threat, humiliation and financial problems) are 
known to have depressogenic effects (21-23). The interplay between genetic and 
environmental factors has also been demonstrated using gene-by-environment 
interaction (G x E) studies, in which individuals with a high-risk genetic makeup 
exposed to stressful experiences are at an increased risk of developing depressive 
symptomatology (24, 25). Last but not least, epigenetics provides a mechanistic path 
through which the environment can affect the genome and has emerged as an additional 
disease-explanatory candidate of depression (18). The present thesis includes data from 
epigenetic, genetic and G x E studies of depression. 
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1.1.3. Neuroanatomy 
Neuroimaging studies have demonstrated a number of structural brain abnormalities in 
depressed patients compared to healthy controls. More specifically, patients have been 
found to have increased volumes of the lateral ventricles and decreased volumes of the 
basal ganglia, cingulate cortex, frontal lobe [including the (pre)frontal cortex, 
orbitofrontal cortex and gyrus rectus], hippocampus, striatum, and thalamus (26-28). 
This thesis contains studies investigating two of these regions: the hippocampus (HIP) 
and the prefrontal cortex (PFC). The hippocampus plays an important role in learning, 
memory function and spatial navigation (29 - 31), and its atrophy has been associated 
with depression (32). In particular, the subgranular zone of HIP’s dentate gyrus is one 
of the two established brain regions where adult neurogenesis (i.e. the growth of new 
neurons from neural stem cells) occurs (33). [The second region where adult 
neurogenesis occurs is the subventricular zone which lines the lateral ventricles; (34)] 
Hippocampal adult neurogenesis has been suggested to be important for HIP’s role in 
learning and memory (35), to be stimulated by antidepressant treatment (36) and to be 
required for the behavioral effects of antidepressants (37). The PFC, in its turn, plays an 
important role in higher cognitive functions and cognitive control, such as in 
orchestrating thoughts and actions to fulfill an individual’s internal goals (38-40). Data 
from patients with brain lesions in this region have shown that the PFC is both critically 
and causally involved in the development of depression (41). 
 
1.1.4. Treatment  
The most common ways of treating depression include pharmacotherapy [i.e. 
psychiatric medications like different antidepressant drugs; (42)], psychotherapy [i.e. 
treatment using psychological means like cognitive-behavioral therapy, a.k.a. CBT; 
(43)], electroconvulsive therapy [i.e. electrically induced seizures; (44)], or their 
combination (45). Experimental data also suggest an antidepressant efficacy of drugs 
that can influence certain epigenetic mechanisms (46-48). Additionally, physical 
exercise has been suggested to alleviate depressive symptoms (49). This thesis includes 
studies that examine the molecular and behavioral effects of a) a widely-prescribed 
drug (escitalopram) that belongs to the class of selective serotonin reuptake inhibitors 
(SSRIs), b) an experimental drug (sodium butyrate) that inhibits epigenetic processes, 
and c) physical exercise (running). One of the dissertation’s studies also investigates a 
certain genetic variation that is present in the gene coding for monoamine oxidase A 
(MAOA). Monoamine oxidase inhibitors (MAOIs) belong to a class of antidepressants 
that act by inhibiting the activity of monoamine oxidases (like MAOA) and thus 
prevent the breakdown of monoamine neurotransmitters. 
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1.2. DEPRESSION – THE NEUROCHEMICAL PERSPECTIVE 
Based on biochemical and psychopharmacological data derived from experimental and 
clinical studies of depression, a number of theories and models have been proposed to 
explain its neurochemical basis (50, 51). The present thesis includes studies that are 
related to the monoamine, the stress-diathesis, and the neurogenesis hypotheses of 
depression.  
 
 
1.2.1. The monoamine neurotransmitter hypothesis 
Monoamine neurotransmitters regulate the central nervous system and assist in the 
transmittance of signals –across a synapse– from a neuron to a target cell. They are 
termed monoamines as they contain one amino group, which is connected to an 
aromatic ring by a two-carbon chain. Based on the monoamine hypothesis, depression 
arises from a neurochemical imbalance that leads to a defective monoamine 
neurotransmission. This imbalance may occur as a result of a deficiency of major 
monoamine neurotransmitters [such as dopamine, serotonin, and norepinephrine (a.k.a. 
noradrenaline)] in the synaptic cleft or of their corresponding receptors and regulators. 
In line with this hypothesis, the majority of antidepressants act by increasing the brain 
levels of one or more of these neurotransmitters. For instance, SSRIs and MAOIs block 
the reuptake of serotonin from the synaptic cleft and hinder the breakdown of 
neurotransmitters, respectively. Two genes that are involved in the monoamine 
hypothesis and are studied in the constituent papers of this thesis are P11 (a.k.a. 
S100A10) and MAOA. P11 regulates the efficacy of serotonergic neurotransmission 
(52) by interacting with and enhancing the availability of serotonin receptors 
(especially 5-HT1B and 5-HT4) at the cell membrane (53, 54). MAOA, on the other 
hand, codes for a mitochondrial enzyme that catabolizes the major aforementioned 
neurotransmitters [dopamine, serotonin, and norepinephrine; (55)]. 
 
1.2.2. The HPA axis and the stress-diathesis hypothesis 
The hypothalamic-pituitary-adrenal (HPA) axis is thought to mediate the psychological 
and/or physical experience of stress (56). In particular, the corticotropin-releasing 
hormone (CRH) can be released by the hypothalamus in response to stressful events. 
CRH stimulates the release of adrenocorticotropic hormone (ACTH) from the pituitary, 
which activates the HPA axis and ultimately leads to the release of glucocorticoids (e.g. 
cortisol). Glucocorticoids, in their turn, bind to their receptor [the nuclear receptor 
subfamily 3, group C, member 1; NR3C1 (a.k.a. glucocorticoid receptor; GR)] which, 
in healthy conditions, leads to a negative-feedback regulation to maintain homeostasis. 
According to the stress-diathesis model, depression is thought to develop as a result of 
a biological/genetic vulnerability of the HPA axis in combination with stress from life 
experiences. For instance, an HPA axis overdrive has been observed in depression (57, 
58) and one of the underlying causes may be the reduced levels of NR3C1 (59, 60). 
The transcriptional activity of NR3C1 is known to be regulated by epigenetic 
mechanisms that are studied in the present thesis. Agents acting as agonists for NR3C1 
(e.g. dexamethasones) have shown better effectiveness than placebos in treating 
depression (61) and CRF receptor antagonists are being tested in clinical trials (62).  
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1.2.3. Neuropeptides, neurotrophins and the neurogenesis hypothesis 
Neuropeptides are signaling molecules (e.g. the already mentioned CRH) that mediate 
or modulate neuronal communication and neuronal function, and neurotrophins are 
proteins that induce neuronal survival, growth and plasticity. With regard to 
neuropeptides, galanin, neuropeptide S (NPS), neuropeptide Y (NPY), substance P and 
vasopressin, belong to those that have been shown to affect stress responses (63-65), 
and some of them are currently serving as the base for the development of potential 
novel therapeutics for the treatment of depression and anxiety disorders (66). With 
regard to neurotrophins, brain-derived neurotrophic factor (BDNF), nerve growth factor 
(NGF), neurotrophin-3 (NT-3), and vascular endothelial growth factor (VEGF), belong 
to those that have been associated with mood disorders (67). A common function of 
certain neuropeptides and most neurotrophins, and which has been linked to depression, 
is the promotion of neurogenesis (68). The neuropeptide that is studied within the 
present thesis is NPY, which has been shown both to promote hippocampal 
neurogenesis (69-72) and to be associated with anxiety, depression and stress (73, 74). 
NPY is highly conserved among species, is widely expressed in the central nervous 
system (CNS) and is thought to confer mental resilience (75-78) through the interaction 
with its receptors [particularly NPY-Y1 receptors; (79)]. 
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1.3. DEPRESSION – THE GENETIC PERSPECTIVE 
The comparison of monozygotic and dizygotic twins, with regard to the concordance 
rates of psychiatric disorders, has shown that depression has a heritability of ~36% (19, 
20). The latter represents a numerical estimate of the contribution of genetics to disease 
manifestation. Although not always consistent, genetic studies have been able to 
pinpoint some genetic loci that are associated with depression (80). The present thesis 
includes genetic association and G x E interaction studies of depression with respect to 
NPY and MAOA, respectively. 
 
 
1.3.1. The neuropeptide Y gene 
The NPY gene codes for a premature form of NPY (preproNPY) that consists of a 
signal peptide, followed by the mature NPY, a processing site, and a C-terminal peptide 
(81). A functional single nucleotide polymorphism (SNP) has been identified in the 
human NPY gene that leads to an amino acid (a.a.) substitution in NPY’s signal peptide 
and affects preproNPY’s processing into mature NPY (82). More specifically, the so-
called Leu7/Pro7 genotype has been shown to lead to ~40% higher NPY levels in the 
plasma compared to the Leu7/Leu7 genotype (82). Genetic studies investigating this 
genetic polymorphism have found an association between this SNP and depression (83-
85). The human NPY promoter has also been shown to harbor a functional SNP that 
controls NPY’s transcriptional activity (86) and is known to affect emotional processing 
and stress responses (86-88). The effects of NPY’s genetic variations have also been 
shown to be modulated by childhood adversities, in line with a G x E interaction model 
(89-92). In the present thesis, Npy was also studied with respect to alternative splicing; 
a pre-messenger RNA (pre-mRNA) regulatory mechanism which produces a number of 
different mRNAs using the same DNA template. Alternative splicing is important in 
enhancing an organism’s transcriptome and proteome repertoires (93), and its 
dysregulation is associated with human disease (94). 
 
1.3.2. The monoamine oxidase A gene 
Whereas P11, NR3C1 and NPY are all autosomal genes, the MAOA gene is X-linked. 
This means that the gene is located on the X chromosome, making females carriers of 
two MAOA copies while males have only one copy of the gene. In order for females not 
to have twice as many X-linked gene products as males, female organisms employ a 
process termed X-chromosome inactivation (XCI). During this procedure, one of the X 
chromosomes is silenced mainly through epigenetic procedures (95, 96). Even if some 
genes have been proposed to escape XCI (97), most reports on MAOA suggest that it is 
subjected to this event (98-101). MAOA is also known to contain a functional genetic 
length polymorphism in its promoter region (termed upstream variable-number tandem 
repeat; u-VNTR) that affects transcriptional activity in vitro (102-104). The MAOA u-
VNTR has been associated with conduct (e.g. aggressive and antisocial) behavior in 
male individuals, particularly when exposed to childhood maltreatment, demonstrating 
a G x E interaction (105-110). The MAOA u-VNTR has also been associated with 
depressive symptomatology both alone (111-114) and in combination with childhood 
adversities (25). 
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1.4. DEPRESSION – THE EPIGENETIC PERSPECTIVE 
Epigenetics is considered as one of the most rapidly expanding biological fields and its 
definition is constantly evolving as new epigenetic marks are being discovered and 
their function is becoming clear. A recent scientific meeting proposed a definition of 
“an epigenetic trait (being) a stably heritable phenotype resulting from changes in a 
chromosome without alterations in the DNA sequence” [p. 781 of (115)]. Epigenetic 
marks include DNA methylation, histone modifications, microRNAs (miRNAs) and 
nucleosome positioning, all of which are critical for the regulation of cellular processes 
such as differentiation, DNA-protein interactions, embryogenesis, gene expression, 
genomic stability, imprinting, and X-chromosome inactivation (116). Two types of 
epigenetic modifications have been studied with respect to depression in the present 
thesis: a) DNA methylation, and b) histone modifications. 
 
 
1.4.1. DNA methylation  
DNA methylation involves the covalent binding of a methyl group to the 5-carbon 
position of the cytosine residues within CpG dinucleotides of the mammalian genome 
and, to date, a number of human diseases have been associated with aberrations in this 
type of epigenetic mark (117). In general, genome-wide DNA methylation is associated 
with genomic stability (118) and DNA hypermethylation within a gene’s promoter 
region and first exon is linked to gene expression silencing (119, 120). With regard to 
genomic stability, DNA methylation is known to silence transposable elements, i.e. 
DNA sequences that have the ability to “jump around” the genome (121). The ways by 
which DNA methylation can affect gene expression have been summarized by two 
main models; the critical site and the methylation density models (122). The first model 
refers to distinct DNA elements –usually located in a gene’s promoter region– whose 
methylation leads to gene silencing through the binding inhibition of a transcription 
activator [e.g. a transcription factor (TF)]. The second model collectively investigates 
numerous CpG sites [e.g. at CpG-rich regions, usually referred to as CpG islands; 
(123)] and regards high methylation levels as an inactivating chromatin structure 
determinant. DNA methylation is catalyzed by three main enzymes [DNMT1, 
DNMT3a and DNMT3b; (124, 125)] and can be inhibited by certain pharmacological 
agents, such as 5-aza-2’deoxycytidine (126). DNA demethylation, on the other hand, is 
thought to occur through the action of proteins of the ten-eleven translocation (TET) 
family (127, 128) and to be promoted by proteins like the growth arrest and DNA-
damage-inducible, beta [GADD45b; (129) ]. With regard to psychopathology, perhaps 
the most prominent findings to date originate from DNA methylation studies of 
NR3C1. More specifically, childhood adversities in the form of maternal separation in 
rodents (130, 131) and abuse in humans (132) have been associated with DNA 
hypermethylation of the promoter region of NR3C1. The primary methylation model 
examined in these studies has been that of the critical site model, with CpG methylation 
in the NR3C1 region interfering with the binding of the nerve growth factor-induced 
protein A (NGFI-A) TF that leads to decreased expression levels of this HPA-axis-
related component (131, 132). 
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1.4.2. Histone modifications  
Nucleosomes serve as the basic DNA packaging units in the cell nuclei of eukaryotes, 
and each nucleosome consists of ~147 base pairs (bp) of DNA wrapped around an 
octamer of two copies of the core histone proteins: H2A, H2B, H3, and H4 (133). A 
second widely studied epigenetic mark is that of the post-translational modifications of 
the histone proteins’ N-terminal tails. These modifications include acetylation, 
methylation, phosphorylation and ubiquitination, and they can all alter the chromatin 
architecture in a way that either increases or decreases the permissiveness of the 
transcriptional machinery that controls gene-expression activity (134-136). In the 
present thesis, the modification that has primarily been studied is histone acetylation; a 
histone modification that neutralizes the positive charge of histones’ lysine residues. 
The latter decreases the histone interactions with the negatively charged DNA, and is 
associated with decondensed chromatin (so-called euchromatin) and increased gene 
activity (134-136). Deacetylation, on the other hand, leads to condensed chromatin (so-
called heterochromatin) that is associated with transcriptional repression (134-136). 
Acetylation and deacetylation reactions are catalyzed by histone acetyltransferases 
(HATs) and histone deacetylases (HDACs), respectively, and can be pharmacologically 
manipulated with the use of appropriate agents (e.g. trichostatin A and sodium butyrate 
which act as HDAC inhibitors; HDACi). With regard to depression, it has been shown 
that electroconvulsive therapy and other antidepressant agents (e.g. imipramine) lead to 
activating histone modifications, decreased expression of certain HDACs, and 
increased mRNA levels of neurotrophins like Bdnf (48, 137). It has also been shown 
that HDACi, like sodium butyrate, have antidepressant-like effects (47) and physical 
exercise (running) increases histone acetylation (138). 
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1.5. BIOBANKS 
The Swedish Act on Biobanks (SF 2002:297) defines the concept biobank as 
“biological material from one or several human beings collected and stored indefinitely 
or for a specified time and whose origin can be traced to the human or humans from 
whom it originates” [(139); translation from (140)] and The Swedish National Biobank 
Program states that the usage of a biobank is primarily to: 1) enhance patient disease 
diagnostics, 2) control epidemic infectious diseases, 3) educate medical personnel, 4) 
document clinical analyses and allow for re-analyses, and 5) enhance medical research 
and quality follow-up of medical care.  
 
 
1.5.1. DNA biobanks and complex disorders 
With the human genome available (141, 142), biobank repositories of DNA samples –
preferably combined with health history data– have acquired a crucial role in the 
identification of genetic elements associated with complex disorders like depression 
(143). Indeed, the human studies included in the present thesis were performed with 
genetic material from DNA biobanks. The latter collect, store and handle DNA from 
human subjects, with the primary purpose in this dissertation’s studies being the 
enhancement of medical research particularly in the field of psychiatric genetics and 
epigenetics. However, the success of these genetic databases in promoting research 
depends on public participation and acquiescence, as thousands of individuals are 
needed for detecting depression-associated genetic loci that are known to have low 
effect-sizes (144). As only few DNA biobanks can achieve this number of samples on 
their own, access to genetic data across different studies has been recognized as an 
important factor for identifying new associations, via so-called genome-wide 
association studies [GWAS; (145)]. 
 
1.5.2. Legal and ethical issues  
The legal and ethical requirements when setting up a biobank for medical research 
usually entail the acquisition of an informed consent through which the individual, 
whose biological samples will be gathered and used, is informed about the purpose of 
the research and how the provided material will be used, and gives his/her approval 
(146). To seek an informed consent is viewed as an act of respect for the subject’s 
autonomy, whereas signing the consent is an indication of public trust in biobank 
research (147). However, according to WHO “no regulatory framework for genetic 
databases has been developed to date that is global in scope yet developed with regional 
input, while being specific enough to provide practical guidance” (148). There is thus a 
risk of failing to attain public acceptance due to insufficient forms of confidentiality, 
anti-discriminatory and privacy measures, which brings the principle of solidarity, i.e. 
research participation for the common good, at stake for DNA biobanks (149, 150). A 
means of building trust and reciprocity with potential participants is benefit sharing; 
broadly defined as the equitable distribution of benefits deriving from the utilization of 
genetic resources (151). The last paper in the present thesis, examines the reasons for 
why certain individuals bypass solidarity and refuse to consent to DNA biobanking.  
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2. AIMS 
The general aim of this thesis was to increase the understanding of depression’s 
pathophysiology and to raise some ethical issues associated with human genetic 
biobanking. Several specific aims were also defined a priori, or arose during the course 
of the experimental procedures. 
 
 
These specific aims were to: 
 
• Study the association of P11 with depression using a genetic animal model, and 
explore the epigenetic mechanisms that govern P11 gene expression both in 
naïve (untreated) states and also in response to antidepressant treatment with 
SSRIs. 
• Try to replicate the association of a functional SNP, in the human NPY gene, 
with depression. 
• Investigate the genetic and/or epigenetic components responsible for the 
decreased levels of Npy in an animal model of depression-like states, and study 
the effects of different treatment interventions on Npy expression. 
• Characterize novel mRNA splice-variants of Npy that are present in the rat 
brain. 
• Test whether the human MAOA u-VNTR interacts with childhood adversities to 
increase the risk of depression, and whether the u-VNTR may mediate the 
association between childhood adversities and DNA methylation of NR3C1. 
• Quantify the DNA methylation of a MAOA region and examine the putative 
association with depression in humans. 
• Examine the concordance of DNA methylation levels, of MAOA and NR3C1, 
between DNA extracted from human blood and saliva. 
• Identify the reasons behind the public’s decision to refuse to provide DNA 
when requested to do so for research purposes. 
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3. MATERIAL AND METHODS 
The following section provides a brief overview of the material and methods that were 
used in the thesis’ constituent papers. If not otherwise stated, all generated data were 
analyzed using appropriate statistical methods. All experiments and methodologies 
were reviewed and approved by appropriate ethical committees. 
 
 
3.1. HUMAN STUDIES 
Human investigations presented in this thesis included genetic and epigenetic analyses, 
as well as the study of the motivations for not consenting to DNA biobanking. All 
human studies were performed using participants from the PART study. 
 
3.1.1. The PART study 
PART (Psykisk hälsa, Arbete, RelaTioner) is a longitudinal (three waves) population-
based study of mental health, work and relation conditions, performed in Stockholm 
County, Sweden. It started in 1998 and has been based on questionnaires and subgroup 
psychiatric interviews (152). The questionnaires covered demographic, socioeconomic 
and somatic-health data, and screening instruments for psychological wellbeing, 
psychiatric symptoms, social disability and alcohol/drug abuse. The interviews 
evaluated psychiatric symptoms, life events and working conditions. The PART 
database has also been enriched with complementary data deriving from diverse 
national registries. PART’s first wave (PART I) was conducted during the period 1998-
2000 and responses were obtained from 10441 participants leading to a participation 
rate of 53%. When non-participants were contacted by telephone, the main reason 
given for not responding was that the questionnaire concerned sensitive issues (153). 
PART’s second wave (PART II) was conducted during the period 2001-2003 and used 
a supplemented version of PART I’s questionnaire. Out of 10303 eligible PART I 
participants, 8613 responded, leading to a participation rate of 84%. An extensive non-
participation analysis was performed using available official registries. Participation 
was associated with female gender, higher age, income and education, being born in the 
Nordic countries, and having no psychiatric diagnosis in the hospital discharge and the 
early retirement registries. The associations between age, gender, income, country of 
origin, and in-patient hospital care due to psychiatric diagnosis were calculated for 
participants and non-participants, separately, and the OR’s for these associations were 
similar among the two groups (153, 154). PART’s third wave (PART III) was 
conducted during 2011. No kind of incentive has been offered throughout the PART 
study, making participation rely on a pure voluntary act.  
 
3.1.2. DNA biobanking of PART 
During the period 2006-2007 a total of 5527 PART II subjects were requested to 
contribute genetic material to PART’s DNA biobank that aimed at investigating genetic 
elements responsible for stress and wellbeing. All individuals received a mail package 
containing a self-administered saliva kit and a prepaid mail packet for specimen return. 
They also received instructions for using the saliva collection kit, a specified informed 
consent form and an information letter. The latter stated the confidentiality rules, the 
coding procedures and the DNA storage within the Karolinska Institutet, and according 
to the biobank law that protects the individual’s integrity. The participation rate of the 
DNA biobanking wave was 54.6% (n = 3018 participants). A subset of individuals was 
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also requested to contribute blood samples. Thus, DNA extracted from saliva and blood 
was used for the genetic and epigenetic analyses described in the following sections. 
 
3.1.3. Reasons behind non-participation in DNA biobanking  
In order to reveal the public’s reasons behind non-participation in DNA biobanking, 
PART’s DNA biobanking wave was used. In particular, a self-administered structured 
questionnaire was first mailed to non-respondents asking them to state the reasons for 
non-participation (155). Subsequently, a subgroup of individuals who answered the 
questionnaire was interviewed, and responses were analyzed using qualitative content 
analyses methods (156, 157). 
 
3.1.4. Genetic analyses  
Genetic analyses were performed for NPY and MAOA. The genetic analysis of NPY 
investigated the association of a functional NPY SNP (rs16139) with depression and 
SNP genotyping was performed using the Pyrosequencing methodology (85). 
Pyrosequencing is a DNA sequencing method that relies on the detection of 
pyrophosphate release after nucleotide incorporation (158). The genetic analyses of 
MAOA included both DNA sequencing and fragment analyses. DNA sequencing was 
used to determine the exact number of MAOA u-VNTR repeats and was performed 
using dye-terminator sequencing. The latter utilizes four dideoxynucleotide chain 
terminators, each labeled with different fluorescent dyes, which assist in the generation 
of a DNA sequence trace chromatogram after capillary electrophoresis (159). Fragment 
analysis was used to study the MAOA u-VNTR (a minisatellite) and associate it with 
depression. The latter method is based on the amplified fragment length polymorphism 
technique (160). Following capillary electrophoresis, fragment analysis generates a size 
estimate of the length polymorphism under investigation by comparing it to a size 
standard of nucleotide fragments with known lengths. All genetic analyses, as well as 
the epigenetic analyses presented in the next section, incorporate the polymerase chain 
reaction (PCR) as an essential step in the experimental protocols. PCR is probably the 
most widely used technique in molecular biology and entails the amplification of a 
piece of DNA across several orders of magnitude (161). 
 
3.1.5. Epigenetic analyses  
The human epigenetic analyses investigated the DNA methylation levels of gene-
specific regions of MAOA and NR3C1, and tested for association with depression and 
childhood adversities, respectively. These gene-specific DNA methylation studies were 
performed using matrix-assisted laser desorption/ionization time-of-flight (MALDI-
TOF) mass spectrometry of base-specifically cleaved amplification products of 
bisulphite-treated DNA. This technology allows a quantitative assessment of DNA 
methylation levels under high-throughput conditions (162) and incorporates the 
treatment of DNA with bisulfite as an essential preceding step. Bisulfite treatment of 
DNA converts cytosine residues to uracil and leaves methylated cytosine residues 
unaffected, thus allowing the distinction between unmethylated and methylated CpG 
sites of the genome (163). 
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3.2. ANIMAL STUDIES 
Animal studies included genetic, epigenetic, gene-expression, alternative splicing, 
protein, DNA/protein-interaction and behavioral experiments. All animal studies used 
the Flinders Sensitive Line (FSL) as a model of depression-like states and the Flinders 
Resistant Line (FRL) as its controls. 
 
 
3.2.1. The FSL model of depression-like states 
The FSL/FRL model is a genetic rat model, meaning that selective breeding of animals 
was used to generate these lines. When compared to FRL, the FSL line resembles 
human depression and is thus referred to as a depression-like model (164). More 
specifically, the FSL line exhibits both face validity for depression (e.g. psychomotor 
retardation, appetite reduction, sleep disturbances, impaired emotional memory and 
anxiety) and also antidepressant predictive validity [e.g. is successfully used for 
behavioral pharmacological screen of antidepressant drugs; (164, 165)]. In addition, 
neurochemical and molecular data suggest that the FSL rat exhibits changes consistent 
with the monoamine (serotonergic and dopaminergic) and neuropeptide models of 
depression (164). However it should be noted that the FSL does not resemble human 
depression in all aspects. For instance, it shows only stress-induced anhedonic effects, 
and neurochemical data argue against an involvement of the noradrenergic and the 
HPA-axis models of depression (164, 166). The FSL/FRL tissue samples used for the 
experimental procedures included PFC and HIP regions. 
 
3.2.2. Genetic analyses  
The genetic analyses included DNA sequencing of P11 and Npy, and SNP genotyping 
of Npy. As described previously for humans, DNA sequencing was performed using 
dye-terminator sequencing and SNP genotyping was performed through 
Pyrosequencing. 
 
3.2.3. RNA and protein analyses  
Analyses of RNA molecules included gene-expression (mRNA) analyses, of P11 and 
Npy, and examination of alternative splicing, of Npy pre-mRNA. The gene-expression 
analyses included in situ hybridization (ISH) and quantitative Real-Time PCR (qRT-
PCR) experiments. ISH is a hybridization technique that utilizes labeled probes which 
bind to complementary DNA or RNA and allows both for localization and 
quantification of their corresponding levels in a tissue section (167-169). The second 
gene-expression technique, i.e. qRT-PCR, is a PCR-based method that amplifies and 
simultaneously quantifies a targeted DNA or RNA molecule (the RNA exists in the 
form of complementary DNA; cDNA) with the help of fluorescent dyes or reporters 
(170). Alternative splicing of pre-mRNA was examined using Rapid Amplification of 
cDNA Ends (RACE); a method used to obtain the full length sequences of mRNA 
transcripts and allows for the identification of putative splice variants (171). The 
protein analyses were performed by immunoblotting [a.k.a. Western blotting; (172)] 
techniques to detect and quantify protein levels of P11 and to detect putative protein 
isoforms corresponding to the Npy mRNAs splice variants.  
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3.2.4. Transcriptional activity and DNA/protein interaction analyses  
To assess transcriptional activity of the different genetic variations present in the Npy 
promoter region, a luciferase reporter assay was utilized. In these bioluminescent 
experiments, cells are transfected with a genetic construct that contains the promoter 
region under investigation, placed upstream of the luciferase gene, which leads to the 
emission of light whose level is positively correlated with the gene-activity (173). To 
investigate putative DNA/protein interactions related to P11 and Npy, three types of 
analyses were performed: in silico, in vitro and in vivo analyses. The in silico analyses 
were performed with the help of web-based tools that assist in the prediction of cis-
regulatory elements and may provide clues about the proteins binding at a specific 
nucleotide sequence (174). The in vitro analyses included electrophoretic mobility shift 
assays (EMSA). An EMSA will reveal a DNA/protein interaction in the form of a gel 
shift following an electrophoretic separation of a mixture containing the 
probe/sequence of interest and a protein extract (175). The in vivo interactions analyses 
were performed using chromatin immunoprecipitation (ChIP). ChIP involves the cross-
linking between chromatin and an associated protein, which is followed by an 
immunoprecipitation stage, a reversal of the cross-linking and a DNA quantification 
stage that yields data corresponding to the presumed interaction (176).  
 
3.2.5. Epigenetic analyses  
The epigenetic analyses included both DNA methylation and histone modification 
experiments. DNA methylation was performed both for gene-specific regions and 
globally for the entire genome. The gene-specific DNA methylation analyses were 
conducted for a P11 promoter region with the help of Pyrosequencing technology after 
bisulfite treatment of the DNA (177). Global DNA methylation was assessed at CCGG 
sites throughout the genome using the LUminometric Methylation Assay (LUMA), 
which involves the DNA cleavage with methylation-sensitive and methylation-
insensitive restriction enzymes followed by a quantification using Pyrosequencing 
(178). ChIP, described in the previous section, can also be modified for the study of 
histone modifications using appropriate antibodies (179) and was utilized for the 
investigation of certain histone marks at the Npy locus.  
 
3.2.6. Treatments and behavioral models  
Three types of treatment interventions and one type of behavioral experiment were 
utilized. Specifically, animals were subjected to SSRI (escitalopram), HDACi (sodium 
butyrate), and physical exercise (running) interventions. The behavioral model of 
depression used was the Porsolt test (a.k.a. behavioral despair test or forced swimming 
test; FST) that is considered to have an excellent predictive validity for antidepressants 
(180) and to be analogous to behavioral despair that is observed in depression (181). 
During this experiment, the rat is placed in a cylindrical glass that is filled with water 
and the swimming, climbing, and floating (immobility) times are scored. The expected 
outcome of an effective antidepressant is to decrease the floating time and/or increase 
the swimming or climbing time.  
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4. SUMMARY OF PAPERS AND RESULTS  
This section provides a summary of the thesis’ constituent papers by presenting their 
titles, background, purpose, main findings and conclusions. 
 
 
4.1. PAPER I 
 
4.1.1. Title 
Antidepressant treatment is associated with epigenetic alterations in the promoter of 
P11 in a genetic model of depression. 
 
4.1.2. Background 
P11 levels have been found to be decreased in postmortem brain tissues of depressed 
subjects and in an animal model of depression (53, 182). In addition, p11 knockout 
mice display a depression-like phenotype and p11 gene therapy reverses depressed 
behaviors in animals (53, 183). Different antidepressant therapies have been associated 
with increased P11 levels (53, 184, 185) and DNA methylation has been shown to 
plays a role in p11’s transcriptional regulation (186, 187). 
 
4.1.3. Purpose 
To investigate potential P11 mRNA and protein differences in the PFC between the 
FSL and the FRL lines and explore possible DNA methylation contributors, as well as, 
effects of SSRI treatment. 
 
4.1.4. Main findings 
FSL had decreased levels of P11 in the PFC which were associated with higher DNA 
methylation levels in P11’s promoter region. SSRI treatment in FSL was associated 
with an increase of p11 mRNA levels, a restoration of the DNA methylation pattern, 
and a reduction of Dnmt1 and Dnmt3a mRNA levels. 
 
4.1.5. Conclusion 
P11 is associated with depression-like states and appears to be controlled by DNA 
methylation mechanisms that can be affected by antidepressant treatment with SSRIs.  
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4.2. PAPER II 
 
4.2.1. Title 
PreproNPY Pro7 protects against depression despite exposure to environmental risk 
factors.  
 
4.2.2. Background 
The functional SNP rs16139 (Leu7Pro, T1128C) has been associated with depression 
in humans (83, 84). This a.a. substitution lies within NPY’s signal peptide and affects 
the processing of NPY’s premature form (preproNPY) into mature NPY, with the C 
allele (Pro) leading to higher plasma NPY levels (82).  
 
4.2.3. Purpose 
To investigate the putative association of this SNP with depression and/or anxiety using 
the PART cohort. 
 
4.2.4. Main findings 
The Leu7Pro SNP was associated with depression and there was a tendency for 
association with anxiety. Specifically, Pro7 was rarer in subjects with depression 
suggesting a protective role of NPY that was also evident by studying healthy 
individuals exposed to environmental risk factors of depression.  
 
4.2.5. Conclusion 
Given that PreproNPY Pro7 leads to increased levels of NPY, this investigation is in 
line with the literature supporting a role for this neuropeptide in promoting mental 
resiliency. 
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4.3. PAPER III 
 
4.3.1. Title 
Allele-specific epigenetic programming of neuropeptide Y (Npy) in depression-like 
states. 
 
4.3.2. Background 
The human NPY promoter contains a functional SNP (C/T; rs16147) that controls 
NPY’s transcriptional activity (86) and affects emotional processing and stress response 
(86-88). The molecular mechanisms that underlie this transcriptional regulation remain 
however unknown. The FSL rat model is known to have decreased Npy levels 
compared to FRL (188-192). 
 
4.3.3. Purpose 
To investigate the putative genetic and/or epigenetic regulatory mechanisms leading to 
the aberrant Npy expression in FSL, in addition to testing the effects of HDACi 
administration and physical exercise (running) on Npy expression. 
 
4.3.4. Main findings 
The FSL/FRL model harbors a functional rat SNP in the Npy promoter region, similar 
to the one present in humans, which appears to control gene expression in an allele-
specific manner. This allele-specific regulation was mediated by the binding of the 
CREB2 transcription factor and the Ep300 co-activator. Accordingly, Ep300’s histone 
acetyltransferase activity was associated with specific histone modifications. Running, 
but not HDACi administration, increased Npy gene expression. 
 
4.3.5. Conclusion 
Npy gene expression is associated with epigenetic modifications that are influenced by 
SNPs in the promoter region and may be affected by physical exercise. 
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4.4. PAPER IV 
 
4.4.1. Title 
Neuropeptide Y: Identification of a novel rat mRNA splice-variant that is 
downregulated in the hippocampus and the prefrontal cortex of a depression-like 
model.  
 
4.4.2. Background 
Most genes are considered to undergo alternative splicing and dysregulation of this 
post-translation process can cause disease (94). However, there is no knowledge about 
the existence of Npy splice variants. 
 
4.4.3. Purpose 
To investigate the presence of novel Npy splice variants in different rat brain regions 
and examine their association with depression-like states. 
 
4.4.4. Main findings 
A novel “short” mRNA splice variant of Npy was found in five examined rat brain 
regions. This “short” Npy mRNA appeared to be non-coding, to have the same 
transcription start site (TSS), and to be expressed in lower levels, compared the longer 
mRNA counterpart. The FSL model had reduced mRNA levels of both Npy mRNA 
variants.  
 
4.4.5. Conclusion 
Npy undergoes alternative splicing, but with an unknown function of the newly 
identified non-coding “short” mRNA. 
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4.5. PAPER V 
 
4.5.1. Title 
Monoamine oxidase A (MAOA) gene-environment and epigenetic associations with 
depression in females, and MAOA’s action as a mediator of the association between 
childhood adversities and hypermethylation of the glucocorticoid receptor.  
 
4.5.2. Background 
MAOA’s promoter contains a functional length polymorphism (u-VNTR) that, given 
the presence of childhood maltreatment, has been associated with conduct behavior in 
males (105-110) and with depression in youth (25). In addition, MAOA has been found 
to be regulated by DNA methylation (193). Childhood adversities have been associated 
with DNA hypermethylation and decreased expression levels of NR3C1 (130-132, 
194). There is little knowledge about how the DNA methylation statuses of genes 
correlate between different tissues. 
 
4.5.3. Purpose 
To investigate a putative G x E interaction between the MAOA u-VNTR and childhood 
adversities that potentially increases the risk of depression. To examine the DNA 
methylation status of MAOA and test for an association with depression. To test 
whether the MAOA u-VNTR may mediate the effect of early-life adversities on the 
DNA methylation status of NR3C1. To examine the concordance of MAOA and NR3C1 
DNA methylation between saliva and blood samples.   
 
4.5.4. Main findings 
Female individuals with childhood adversities that carried the MAOA u-VNTR leading 
to low in vitro gene expression, had an increased risk of developing depression. In 
addition, MAOA was hypomethylated in depressed female individuals compared to 
controls, and the u-VNTR appeared to mediate the association of parental death with 
hypermethylation of NR3C1. When comparing the mean DNA methylation levels of 
MAOA and NR3C1 between saliva and blood, some gene- and gender-specific 
differences were found.  
 
4.5.5. Conclusion 
Both a G x E interaction and an epigenetic dysregulation of MAOA are associated with 
depression. In addition, an NR3C1 hypermethylation resulting from early-life trauma 
may be mediated by variations of the MAOA u-VNTR, suggesting a common link 
between these two loci. Finally, when conducting gene-specific epigenetic analyses, it 
is important to take into consideration factors like gender and tissue type. 
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4.6. PAPER VI 
 
4.6.1. Title 
Examining the public refusal to consent to DNA biobanking: empirical data from a 
Swedish population-based study.  
 
4.6.2. Background 
Extensive biomedical datasets and DNA biobanks are essential in order to identify 
genes, gene-gene and gene-environment interactions contributing to complex human 
disorders like depression. Public acceptance and participation is thus a mandatory 
component, but most studies have only explored the in theory public opinion towards 
tissue donation, DNA information usage and genetic discrimination (195-199). 
 
4.6.3. Purpose 
To explore, in a pragmatic and empirical way, non-participation in DNA biobanking. 
 
4.6.4. Main findings 
Refusing to participate in DNA biobanking was motivated by two main reasons: lack of 
personal relevance and discomfort related to the DNA being used for alternative 
purposes. Interviews, with subjects feeling discomfort, revealed an underlying public 
mistrust of DNA biobanks that was associated with concerns about integrity, insecurity, 
privacy and suspiciousness.  
 
4.6.5. Conclusion 
Solidarity seems to be at stake for DNA biobanks and there is a need for stricter 
societal measures that include a solid and reinforced legislation to protect privacy, and 
clear guidelines on benefit sharing.  
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5. DISCUSSION 
This section will provide a brief discussion that is primarily based on the papers’ 
findings, their potential clinical relevance, and it will also present some future 
experimental perspectives. 
 
 
5.1. IN GENERAL 
Numerous studies have tried to unravel the pathophysiology of depression but have 
been hindered by the disease’s heterogeneous nature and the need for thousands of 
depressed individuals to identify novel susceptibility genetic loci (50, 51). The first five 
constituent papers of this thesis have combined genetic, epigenetic, molecular and 
behavioral techniques to study depression and depression-like states in humans and 
animal models, respectively. Overall, these data support the complex etiological nature 
of this psychiatric disorder; with a number of genes being associated with depressive 
symptomatology. Interestingly, these associations do not only lie on the genetic level 
but also incorporate epigenetic modifications, like DNA methylation and histone 
modifications, which are in line with an epigenetic hypothesis of 
neuropsychopathology (200). The administration of agents with potential 
antidepressant effects, in combination with the study of their molecular outcomes, has 
also provided some additional insights into the epigenotypic architecture of depression. 
Finally, the last (sixth) constituent paper of the thesis, by studying why the public may 
refuse to donate DNA samples, may assist in the development of more comprehensive 
DNA biobanks that take into account, and do not diminish, core bioethical principles. 
Last but not least, as in almost all conducted research, it should be acknowledged that 
each paper and its corresponding study design comes with a number of technical and 
biological limitations that must be taken into consideration when interpreting the 
results. An effort to summarize these limitations has been made and they are presented 
in the discussion section of each paper.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   23 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
 
 
                  Image property of Philippe A. Melas. Unknown by unknown 
 
 
 
 
 
 
 
 24 
5.2. GENETIC FINDINGS 
Even if achieving reproducibility in associations between candidate genes and 
depression has been a major scientific problem (83), the data generated by separate 
genetic studies have been able to increase the knowledge about the disorder’s genetic 
component (80). For example, linkage has been proposed between different 
chromosomal locations and depression [e.g. 3p25-26 and 15q25-q26; (201, 202)]. 
Specific genes [e.g. NPY, TNF, and genes coding for neurotransmitter transporters; (83, 
203, 204)] and G x E interactions [e.g. 5-HTTLPR and/or MAOA u-VNTR interacting 
with childhood maltreatment; (24, 25)] have also been associated with depression. The 
genetic association data from this dissertation’s papers replicated the involvement of 
NPY in depression (85) and provided some new evidence for a G x E interaction of 
MAOA that increased the risk of depression, particularly in females. With regard to 
NPY, the genetic data are in agreement with the neuropeptide’s role in conferring 
mental resilience (75-78). In addition, a novel non-coding Npy mRNA splice variant 
was found in the rat brain (205) which, due to the high homology of Npy between rat 
and human (206), could indicate this variant’s presence in humans, but with a currently 
unknown function. Finally, with regard to MAOA, the G x E data suggest that carrying 
a certain u-VNTR allele, with a low in vitro transcriptional activity, and having been 
exposed to childhood adversities will increase the risk of depression in adulthood, 
especially in females. This is also in agreement with previous MAOA studies suggesting 
that genetic factors predispose to psychopathology by affecting the sensitivity towards 
adverse and stressful environmental influences (25, 105-110). 
 
 
5.3. EPIGENETIC FINDINGS 
A general consensus in complex disorders, like depression, is that disease development 
usually requires the presence of environmental risk factors. In addition, data supporting 
an epigenetic dysregulation in different psychiatric disorders have been accumulating 
during the past decade (18, 200, 207). Thus, epigenetics has served as an attractive 
candidate in this mediatory interplay between environment and genome, as epigenetic 
modifications can be influenced by environmental and stochastic events, and can be 
transmitted both mitotically [i.e. from one somatic cell to another; (208)] and also 
transgenerationally [i.e. through the germline; (209)]. In line with an epigenetic 
dysregulation in depression, we found both DNA methylation and histone modification 
aberrations associated with depression or depression-like states. For instance, depressed 
females presented with a hypomethylated pattern of MAOA. This epigenetic 
modification theoretically leads to increased levels of MAOA, which metabolize their 
target neurotransmitters at a higher rate, and can lead to a neurochemical imbalance that 
is in line with the monoamine hypothesis of depression. Accordingly, a positron-
emission tomographic study revealed elevated MAOA levels in the brain of depressed 
individuals (210). DNA methylation changes were also found with respect to NR3C1 
and the presence of certain childhood adversities. In particular, parental loss during 
early life, but not other types of adversities (e.g. parental divorce), was found to affect 
the DNA methylation status of the NR3C1 region under investigation. Interestingly, this 
epigenetic outcome also appeared to be mediated by the MAOA locus. The NR3C1 
methylation data are in agreement with the psychobiological notion of “how adversity 
gets under the skin” (211) and support recent recommendations of trying to distinguish 
and study different types of adversities independently and not as a unitary construct 
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(212). The animal studies, in their turn, showed that DNA methylation changes of P11 
in the PFC are associated with depression-like states (213), and histone modifications 
of Npy in the HIP are dictated by genetic variations and are associated with Npy gene-
activity aberrations. These epigenetic marks were present in the promoter region of the 
genes, and it is noteworthy that a weak human genetic association has been found 
between depression and a P11 SNP located in the promoter region [close to a putative 
transcription factor binding site; (214)], and the same localization feature applies for a 
functional NPY SNP that has been associated with depressive psychopathology and 
anxiety (86-88). It is also of note that both of these epigenetic modifications were 
affected by antidepressant interventions, demonstrating the dynamic nature of 
epigenetic marks compared to the more static state of genetic variations. Even if DNA 
methylation and histone modifications were studied separately in this thesis, it should 
be mentioned that these two modifications are also known to be dependent on each 
other and their crosstalk is thought to be mediated by interactions between histone and 
DNA methyltransferases (215). The animal data also indicated that Npy is regulated by 
a transcription factor that is member of the CREB family, which has the ability of 
recruiting co-activators with histone modifying properties. The latter finding is in line 
with previous human genetic data which have linked CREB1 to depression in females 
(216, 217). CREB is also known to be upregulated by antidepressant treatments and an 
increase in its levels has an antidepressant-like effect in animal models (218). Finally, 
the comparison of the DNA methylation signature of specific genes between different 
peripheral tissues revealed some differences, and these tissue-type differences are 
important to consider especially when conducting epigenetic studies of traits primarily 
related to the brain. In psychiatric disorders, for instance, not only is it highly unknown 
how well epigenetic marks of peripheral tissues correlate with those of the brain, but 
the brain itself is known to acquire region-specific DNA methylation signatures (219).  
 
 
5.4. NON-PARTICIPATION IN DNA BIOBANKS 
While the contribution of genetic research to medical progress is widely acknowledged, 
the development of the scientific field itself has been controversial and overwhelming 
during the past decade. Bioethical and legislative measures have required revision but 
the difficulty in keeping pace with this constant development has been substantial. 
According to a former legal adviser to the US Senate, “we faced a paradox. Law is by 
definition local, but science is by definition global, and so are the legal problems that 
new technologies inspire” (220). In parallel, the ongoing public debate has made people 
realize the potential misuse of genomic data. Characteristically, in 2006 the National 
Institutes of Health (NIH) was described as an “ethical Potemkin village where a 
hollow system appears to provide the illusion of integrity” (221). Previous studies have 
mostly investigated the in theory public opinion towards tissue donation, DNA 
information usage and genetic discrimination, both in the Western (195-197, 199) and 
Eastern world (198). However, the paper presented in this thesis explored such attitudes 
in an empirical way by using the DNA biobanking wave of PART. The two main 
reasons among the public for not consenting to DNA biobanking, as shown by the 
questionnaire completion, were lack of personal relevance of DNA contribution and 
discomfort related to the DNA usage. Further examination of the latter reason, with the 
help of interviews, revealed a public mistrust of DNA biobanks. So even if all 
individuals who denied consenting to DNA biobanking had participated twice before in 
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the PART study (by answering extensive questionnaires), people seem to reconsider 
and reevaluate when it comes to sharing their genetic makeup. In particular, a number 
of interviewees stated that questionnaires (which they had agreed on completing 
before) could not act as an identifiable mean in the same way as the DNA can, making 
questionnaire participation more acceptable. This reference is in accordance with the 
American Society of Human Genetics’ (ASHG) response to the NIH regarding 
genome-wide association studies: “The ASHG is acutely aware that the most accurate 
individual identifier is the DNA sequence itself…It is clear that these available 
genotypes alone…are more accurate identifiers than demographic variables alone...” 
(222). Identifiability in genomic research has been acknowledged as a pivotal concern 
and a number of de-identifying tactics are currently utilized (223). Equally interesting 
was the citation of DNA’s nature as a contributing factor to the distressing view of 
biobank studies. Indeed, compared to clinical data that entail individual phenotypic 
information, genetic material has some unique characteristics: it can predict future 
health risks for both a proband and its blood-related family members, it can be derived 
from minute physical traces and it is an immortal material that can be effectively 
replicated and stored, making its utilization open for endless purposes in the future if 
not exploited in a regulated manner (224). Interestingly, the interview topic aiming at 
identifying prerequisites for future DNA participation conveyed the importance of 
keeping an individual informed and updated. Whereas it is expected that such a process 
would increase the feeling of individual control and probably even the personal 
relevance, the potential problems with e.g. revealing scientific results sometimes 
outweigh this possibility (225). In some instances, when this latter issue was brought 
during the interviews, individuals automatically recognized the potential problems and 
suggested by themselves that being offered the opportunity of choosing whether to get 
to know the results or not would be the best option. In addition, even if interviewees 
mentioned the possible DNA utilization by governmental agencies (e.g. police), there 
was no respondent who referred to the interest of private sectors (e.g. insurance 
companies and employers) in acquiring genetic information. The implications of such a 
potential unawareness are obvious when genetic testing, for instance, can nowadays be 
ordered in an unrestricted way (226). Conclusively, mistrust was shown to be a 
determinant factor in DNA biobank participation, which is in accordance with previous 
studies showing that trust plays a major role in biobank participation (227). This 
mistrust may not only interfere with the acquisition of large cohorts in biological 
studies but, in the case of these feelings being stronger in certain groups, it may also 
introduce a bias in the selection of participants. As a solution, it has been suggested to 
“build greater trust and reciprocity with participants through the equitable approach of 
benefit-sharing” (151), but there is currently no legally binding framework regulating 
benefit sharing for human genetic resources (228) and this needs to be addressed in the 
near future. 
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5.5. CLINICAL SIGNIFICANCE 
The four main genes under investigation (P11, NPY, MAOA and NR3C1) and the data 
generated by studying them, in relation to depression and depression-like states, can 
also be discussed with regard to their putative clinical significance. 
 
• P11: Although an increase in serotonin levels occurs soon after SSRI 
administration (229), clinical studies have consistently shown an unexplained 
~4-6 week therapeutic delay (230). The data from this thesis suggest a 
downstream action of escitalopram, which involves the epigenetic upregulation 
of P11. In combination with previous data that demonstrate the behavioral 
antidepressant effects of SSRIs in the FSL model (231-233), these results are 
both in line with the clinical efficacy of SSRIs and also suggest a putative 
epigenetic mode of action. This epigenetic process may involve multiple 
up/down-stream biochemical steps that collectively require more time than the 
period needed to increase the availability of serotonin in the synaptic cleft, and 
could thus explain the observed therapeutic delays. Interestingly, and in accord 
with the previous assumption, selective agonists of the serotonin 5-HT4 
receptor (the increase of which, on the cell surface, is a downstream effect of 
P11’s action) have been shown to produce rapid (3-4 days) antidepressant 
effects in animals (234). It is worth mentioning that antidepressants have also 
been shown to increase the levels of S100β (235-237). S100β has been 
associated with depression and belongs to the same protein family as P11 (238, 
239). Therefore it has been proposed that the upregulation of different S100 
proteins might be a common characteristic of antidepressant treatments (240). It 
can thus be concluded that a transcriptional deregulation of P11, e.g. via DNA 
hypermethylation, can lead to depression but this state appears to be reversible 
and to be affected by SSRI administration.  
• NPY: The low remission rates of SSRIs [~30% for citalopram; (241)] have 
encouraged the search for more effective antidepressants. Investigating the 
factors that support psychological resilience may thus serve as an alternative 
approach in order to advance in the psychopharmacological field (51). NPY, for 
instance, belongs to one of the best candidates considered to confer mental 
resilience (75-78) and its intranasal administration as a putative antidepressant 
is currently under investigation (74). The data on NPY presented in this thesis 
both support its function in promoting mental resilience and also show that –at 
least in rats– Npy is controlled by histone modifications, highlighting the 
therapeutic potential of agents acting as histone remodelers. Importantly, the 
preliminary data on physical exercise (in the form of rat wheel-running) suggest 
an increase in Npy mRNA expression that is associated with a “rescued” 
behavioral phenotype according to the FST model. This is in line with previous 
studies showing that physical exercise alleviates depressive symptoms and 
increases both hippocampal neurogenesis and Npy expression (49, 242-247). 
Conclusively, these data indicate that running has the potential of serving as a 
non-pharmacological antidepressant substitute that putatively acts through the 
upregulation of NPY and hippocampal neurogenesis. However, further studies 
and trials are needed to determine the exact type and period of exercise needed, 
but also to obtain accurate estimates of effect sizes (248). 
• MAOA and NR3C1: In contrast to the epigenetic analyses of P11 and Npy that 
were conducted using brain regions of the FSL model, the DNA methylation 
analyses of MAOA and NR3C1 were performed using DNA from human 
peripheral tissues. Even if epigenetic aberrations in a peripheral tissue may not 
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account for the actual pathogenesis of a mental illness, they may serve as 
suitable disease or pharmaco-epigenetic biomarkers. MAOA, for example, was 
found to be hypomethylated in depressed individuals, which putatively leads to 
increased MAOA levels which is in line with previous studies showing a 
higher-than-normal abundance of MAOA in the brain of individuals with 
depression (210).  However, as MAOIs are not the first line of choice for the 
treatment of depression due to their increased side-effects compared to e.g. 
SSRIs (249), the DNA methylation data suggest a way to identify the 
individuals that would benefit the most from this type of antidepressant 
medication. With regard to NR3C1, the results showed that adult female 
individuals with depression and with a certain MAOA genotype, who had 
experienced parental loss during childhood, were hypermethylated in the 
NR3C1 promoter region. These data indicate the possibility of using the NR3C1 
methylation status as a biomarker, as individuals with depression and a history 
of childhood adversities have been suggested to benefit more from a 
combinatorial treatment of psychotherapy and pharmacotherapy (250), which 
requires further investigation using randomized control trials. 
 
 
 
 
 
 
 
 
 
             “Healthy mind in a healthy body” 
              -Thales 
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5.6. FUTURE PERSPECTIVES 
Some of the future planned experimental procedures and studies will be mentioned 
before ending this discussion. 
 
• Recent evidence suggests that P11 is regulated by BDNF, thereby proposing an 
additional role of the P11 protein through which neurotrophins may exert their 
antidepressant action (185). The BDNF mRNA exists in nine splice variants in 
the rat (251), which are planned to be examined using the FSL model of 
depression-like states.  
• It was recently shown that methylated cytosine (5-methylcytosine) can be 
converted to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) and 5-
carboxylcytosine (5caC); constituting a pathway for active DNA demethylation 
(127, 128).  The enzymes responsible for these conversions are called Tet1, 
Tet2 and Tet3 (252-254). In particular, 5hmC has been found to be abundant in 
the brain (255) which could suggest a functionality that is related to neuronal 
processes. As the DNA methylation techniques employed in this thesis’ papers 
did not have the capacity to distinguish between the different forms of 
methylated CpG residues (256), it is of importance to investigate the 
contribution of 5hmC in genes whose methylome was associated with 
depression (e.g. P11, MAOA and NR3C1). 
• Besides DNA methylation and histone modifications, a third major epigenetic 
component is a class of RNAs called miRNAs. These are short non-coding 
gene-regulatory RNA sequences that have been implicated in psychiatric 
disorders including schizophrenia, bipolar disorder, and autism (257) and that 
have distinct expression patterns in brain regions critical in depression [e.g. FC 
and HIP; (258)]. For example, miR-22 has been shown to regulate some of the 
genes mentioned earlier in this thesis [e.g. BDNF and MAOA; (259)]. 
However, little is known about their association with depression which requires 
further investigation and is currently ongoing using PFC regions from the FSL 
model. 
• Several of the papers included in this thesis were based on a rodent model of 
depression-like states. Even if depression models can show high face and 
antidepressant predictive validities, and are essential in translational 
neuropsychiatric research, they will never be able to completely model human 
depression as some symptoms (e.g. guilt and suicidality) are impossible to 
reproduce using such systems. This emphasizes the need for reproducing the 
animal findings and testing their relevance using appropriate human material 
(e.g. RNA samples for testing gene expression levels), which is also an ongoing 
project. 
• Finally, benefit sharing was proposed as a solution to address the issues raised 
by non-participation in DNA biobanks. While this concept may be more 
straightforward in cases involving the private sector (e.g. sharing monetary 
amounts deriving from pharmaceutical sales), it is less evident how to deal with 
it in academic research where the direct benefit is nothing more than 
knowledge. The fourth-ranking alternative in the questionnaire of paper VI 
(Alternative D: “I would have wanted to get informed about the results from my 
specimen, but as that is not possible I don’t want to participate”) provides some 
answers to this issue. However, the ethical problems with revealing scientific 
results/knowledge of unknown clinical relevance will most often outweigh this 
possibility. Thus, finding the best ways to bring benefit sharing into practice in 
large-scale genetic research is probably the next area of debate and future study. 
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